- Home
- RERE vs CGEM Comparison
RERE vs CGEM Comparison
Compare RERE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- CGEM
- Stock Information
- Founded
- RERE 2011
- CGEM 2016
- Country
- RERE China
- CGEM United States
- Employees
- RERE N/A
- CGEM N/A
- Industry
- RERE Other Specialty Stores
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- CGEM Health Care
- Exchange
- RERE Nasdaq
- CGEM Nasdaq
- Market Cap
- RERE 444.1M
- CGEM 490.3M
- IPO Year
- RERE 2021
- CGEM 2021
- Fundamental
- Price
- RERE $2.58
- CGEM $8.65
- Analyst Decision
- RERE
- CGEM Strong Buy
- Analyst Count
- RERE 0
- CGEM 4
- Target Price
- RERE N/A
- CGEM $32.00
- AVG Volume (30 Days)
- RERE 847.7K
- CGEM 450.4K
- Earning Date
- RERE 05-20-2025
- CGEM 05-08-2025
- Dividend Yield
- RERE N/A
- CGEM N/A
- EPS Growth
- RERE N/A
- CGEM N/A
- EPS
- RERE 0.07
- CGEM N/A
- Revenue
- RERE $2,388,301,386.00
- CGEM N/A
- Revenue This Year
- RERE $29.57
- CGEM N/A
- Revenue Next Year
- RERE $24.43
- CGEM N/A
- P/E Ratio
- RERE $35.61
- CGEM N/A
- Revenue Growth
- RERE 26.09
- CGEM N/A
- 52 Week Low
- RERE $2.00
- CGEM $6.85
- 52 Week High
- RERE $3.70
- CGEM $24.76
- Technical
- Relative Strength Index (RSI)
- RERE 48.53
- CGEM 62.37
- Support Level
- RERE $2.45
- CGEM $7.73
- Resistance Level
- RERE $2.95
- CGEM $8.00
- Average True Range (ATR)
- RERE 0.15
- CGEM 0.51
- MACD
- RERE -0.01
- CGEM 0.12
- Stochastic Oscillator
- RERE 25.00
- CGEM 89.92
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.